GPX3 suppresses lung adenocarcinoma progression through HSPB1 ubiquitination and Hippo pathway activation.
A robust prognostic model based on manganese metabolism-related genes is established and the critical regulatory role of the GPX3/HSPB1/yes-associated protein (YAP) axis in LUAD progression is uncovered, underscoring the therapeutic potential of targeting GPX3.